{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T21:15:07Z","timestamp":1778793307631,"version":"3.51.4"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T00:00:00Z","timestamp":1769990400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"publisher","award":["21 1842 Pj 01 H"],"award-info":[{"award-number":["21 1842 Pj 01 H"]}],"id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010223","name":"Stiftelsen Jubileumsklinikens Forskningsfond mot Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010223","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007230","name":"Stiftelsen Konung Gustaf V:s Jubileumsfond","doi-asserted-by":"publisher","award":["2021:354 &amp; 2024:571"],"award-info":[{"award-number":["2021:354 &amp; 2024:571"]}],"id":[{"id":"10.13039\/501100007230","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nuclear Medicine and Biology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.nucmedbio.2026.109608","type":"journal-article","created":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T07:15:49Z","timestamp":1770016549000},"page":"109608","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Spontaneous association of different forms of non-conjugated astatine-211 to serum albumin"],"prefix":"10.1016","volume":"154-155","author":[{"given":"Emma","family":"Aneheim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sture","family":"Lindegren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Holger","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tom","family":"B\u00e4ck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.nucmedbio.2026.109608_bb0005","doi-asserted-by":"crossref","DOI":"10.1021\/acs.accounts.1c00327","article-title":"Advances in the chemistry of astatine and implications for the development of radiopharmaceuticals","author":"Guerard","year":"2021","journal-title":"Acc Chem Res"},{"issue":"3","key":"10.1016\/j.nucmedbio.2026.109608_bb0010","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2174\/1874471010801030177","article-title":"Astatine radiopharmaceuticals: prospects and problems","volume":"1","author":"Vaidyanathan","year":"2008","journal-title":"Curr Radiopharm"},{"key":"10.1016\/j.nucmedbio.2026.109608_bb0015","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.ejmech.2016.03.082","article-title":"(211)At-labeled agents for alpha-immunotherapy: on the in vivo stability of astatine-agent bonds","volume":"116","author":"Ayed","year":"2016","journal-title":"Eur J Med Chem"},{"issue":"1","key":"10.1016\/j.nucmedbio.2026.109608_bb0020","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-02614-2","article-title":"Targeted radionuclide therapy with astatine-211: oxidative dehalogenation of astatobenzoate conjugates","volume":"7","author":"Teze","year":"2017","journal-title":"Sci Rep"},{"issue":"supplement 1","key":"10.1016\/j.nucmedbio.2026.109608_bb0025","article-title":"Phase I investigator-initiated clinical trial of targeted alpha therapy using [At]NaAt for refractory thyroid cancer (Alpha-T1 trial)","volume":"66","author":"Watabe","year":"2025","journal-title":"J Nucl Med"},{"issue":"7","key":"10.1016\/j.nucmedbio.2026.109608_bb0030","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1007\/s12149-021-01619-2","article-title":"Manual on the proper use of sodium astatide ([(211)At]NaAt) injections in clinical trials for targeted alpha therapy (1st edition)","volume":"35","author":"Watabe","year":"2021","journal-title":"Ann Nucl Med"},{"issue":"1","key":"10.1016\/j.nucmedbio.2026.109608_bb0035","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s41181-024-00273-z","article-title":"In vitro and in vivo evaluation of a tetrazine-conjugated poly-L-lysine effector molecule labeled with astatine-211","volume":"9","author":"Timperanza","year":"2024","journal-title":"EJNMMI Radiopharm Chem"},{"issue":"7","key":"10.1016\/j.nucmedbio.2026.109608_bb0040","doi-asserted-by":"crossref","first-page":"5234","DOI":"10.1074\/jbc.M110.164848","article-title":"Extending half-life by indirect targeting of the neonatal Fc receptor (FcRn) using a minimal albumin binding domain","volume":"286","author":"Andersen","year":"2011","journal-title":"J Biol Chem"},{"issue":"9","key":"10.1016\/j.nucmedbio.2026.109608_bb0045","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.1007\/s00259-024-06695-w","article-title":"Optimizing the pharmacokinetics of an (211)At-labeled RGD peptide with an albumin-binding moiety via the administration of an albumin-binding inhibitor","volume":"51","author":"Echigo","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"10.1016\/j.nucmedbio.2026.109608_bb0050","doi-asserted-by":"crossref","first-page":"300","DOI":"10.2133\/dmpk.24.300","article-title":"Albumin as fatty acid transporter","volume":"24","author":"van der Vusse","year":"2009","journal-title":"Drug Metab Pharmacokinet"},{"issue":"2a","key":"10.1016\/j.nucmedbio.2026.109608_bb0055","first-page":"1005","article-title":"In vitro effects of free 211At,211At-albumin and 211At-monoclonal antibody compared to external photon irradiation on two human cancer cell lines","volume":"20","author":"Palm","year":"2000","journal-title":"Anticancer Res"},{"issue":"3\u20134","key":"10.1016\/j.nucmedbio.2026.109608_bb0060","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/0047-0740(77)90146-2","article-title":"Preparation of a biologically stable and immunogenically competent astatinated protein","volume":"4","author":"Friedman","year":"1977","journal-title":"Int J Nucl Med Biol"},{"issue":"12","key":"10.1016\/j.nucmedbio.2026.109608_bb0065","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/0020-708X(81)90077-6","article-title":"The nature of the astatine-protein bond","volume":"32","author":"Visser","year":"1981","journal-title":"Int J Appl Radiat Is"},{"issue":"4","key":"10.1016\/j.nucmedbio.2026.109608_bb0070","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/00006231-198604000-00002","article-title":"Animal studies on the in vivo stability of 211At-labelled albumin particles","volume":"7","author":"Wunderlich","year":"1986","journal-title":"Nucl Med Commun"},{"issue":"2\u20133","key":"10.1016\/j.nucmedbio.2026.109608_bb0075","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1524\/ract.1983.33.23.145","article-title":"Inorganic astatine chemistry - formation of complexes of astatine","volume":"33","author":"Visser","year":"1983","journal-title":"Radiochim Acta"},{"issue":"4","key":"10.1016\/j.nucmedbio.2026.109608_bb0080","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0969-8051(97)00230-8","article-title":"Blocking [211At]astatide accumulation in normal tissues: preliminary evaluation of seven potential compounds","volume":"25","author":"Larsen","year":"1998","journal-title":"Nucl Med Biol"},{"issue":"4","key":"10.1016\/j.nucmedbio.2026.109608_bb0085","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/S0969-8051(98)00120-6","article-title":"Astatine-211 labeling of internalizing anti-EGFRvIII monoclonal antibody using N-succinimidyl 5-[211At]astato-3-pyridinecarboxylate","volume":"26","author":"Reist","year":"1999","journal-title":"Nucl Med Biol"},{"issue":"1","key":"10.1016\/j.nucmedbio.2026.109608_bb0090","doi-asserted-by":"crossref","first-page":"9698","DOI":"10.1038\/s41598-024-60615-4","article-title":"Behaviour, use and safety aspects of astatine-211 solvated in chloroform after dry distillation recovery","volume":"14","author":"Aneheim","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.nucmedbio.2026.109608_bb0095","series-title":"Encyclopedia of Food Chemistry","first-page":"74","article-title":"Egg proteins","author":"Snigdha","year":"2019"},{"issue":"21","key":"10.1016\/j.nucmedbio.2026.109608_bb0100","first-page":"283","article-title":"The accumulation, metabolism and biological effects of astatine in rats and monkeys","volume":"2","author":"Hamilton","year":"1953","journal-title":"Univ Calif Publ Pharmacol"},{"issue":"9","key":"10.1016\/j.nucmedbio.2026.109608_bb0105","first-page":"657","article-title":"Biodistribution and dosimetry of free 211At, 125I- and 131I- in rats","volume":"28","author":"Spetz","year":"2013","journal-title":"Cancer Biother Radiopharm"},{"issue":"2","key":"10.1016\/j.nucmedbio.2026.109608_bb0110","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/0026-2862(86)90055-5","article-title":"Concentration of plasma albumin in its accessible space in postmortem human dermis","volume":"32","author":"Bert","year":"1986","journal-title":"Microvasc Res"},{"issue":"12","key":"10.1016\/j.nucmedbio.2026.109608_bb0115","doi-asserted-by":"crossref","first-page":"5444","DOI":"10.1016\/j.bbagen.2013.06.018","article-title":"Binding of transition metal ions to albumin: sites, affinities and rates","volume":"1830","author":"Bal","year":"2013","journal-title":"Biochim Biophys Acta"}],"container-title":["Nuclear Medicine and Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969805126000077?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969805126000077?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T20:58:15Z","timestamp":1778792295000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0969805126000077"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":23,"alternative-id":["S0969805126000077"],"URL":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2026.109608","relation":{},"ISSN":["0969-8051"],"issn-type":[{"value":"0969-8051","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Spontaneous association of different forms of non-conjugated astatine-211 to serum albumin","name":"articletitle","label":"Article Title"},{"value":"Nuclear Medicine and Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2026.109608","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"109608"}}